- Home
- VRAR vs CVKD Comparison
VRAR vs CVKD Comparison
Compare VRAR & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAR
- CVKD
- Stock Information
- Founded
- VRAR 2016
- CVKD 2022
- Country
- VRAR United States
- CVKD United States
- Employees
- VRAR N/A
- CVKD N/A
- Industry
- VRAR Retail: Computer Software & Peripheral Equipment
- CVKD Medicinal Chemicals and Botanical Products
- Sector
- VRAR Technology
- CVKD Health Care
- Exchange
- VRAR Nasdaq
- CVKD Nasdaq
- Market Cap
- VRAR 33.3M
- CVKD 29.5M
- IPO Year
- VRAR 2021
- CVKD 2023
- Fundamental
- Price
- VRAR $1.33
- CVKD $10.28
- Analyst Decision
- VRAR Strong Buy
- CVKD Strong Buy
- Analyst Count
- VRAR 1
- CVKD 1
- Target Price
- VRAR $2.62
- CVKD $32.00
- AVG Volume (30 Days)
- VRAR 139.2K
- CVKD 23.0K
- Earning Date
- VRAR 05-15-2025
- CVKD 08-06-2025
- Dividend Yield
- VRAR N/A
- CVKD N/A
- EPS Growth
- VRAR N/A
- CVKD N/A
- EPS
- VRAR N/A
- CVKD N/A
- Revenue
- VRAR $8,756,789.00
- CVKD N/A
- Revenue This Year
- VRAR $6.59
- CVKD N/A
- Revenue Next Year
- VRAR $30.43
- CVKD N/A
- P/E Ratio
- VRAR N/A
- CVKD N/A
- Revenue Growth
- VRAR N/A
- CVKD N/A
- 52 Week Low
- VRAR $0.50
- CVKD $5.70
- 52 Week High
- VRAR $7.00
- CVKD $22.90
- Technical
- Relative Strength Index (RSI)
- VRAR 45.22
- CVKD 24.53
- Support Level
- VRAR $1.28
- CVKD $10.00
- Resistance Level
- VRAR $1.53
- CVKD $13.30
- Average True Range (ATR)
- VRAR 0.11
- CVKD 0.89
- MACD
- VRAR -0.03
- CVKD -0.39
- Stochastic Oscillator
- VRAR 22.27
- CVKD 4.67
About VRAR The Glimpse Group Inc.
The Glimpse Group Inc is a diversified Virtual and Augmented Reality platform company, comprised of multiple VR and AR software and services companies, and designed with the specific purpose of cultivating companies in the emerging VR/AR industry.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.